Istituto Oncologico Veneto - I.R.C.C.S.

Padua 35128

0 studies enrolling now · 1 studies all time

What they study most

Grade 2 Glioma, Recurrent Glioma, Residual Glioma

Studies at this site

• Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO) — Running, not enrolling